BeOne Medicines Ltd.
BeOne Medicines Ltd. (Nasdaq: ONC) is a global oncology company that discovers, develops and commercializes cancer medicines for patients worldwide. Its portfolio includes BRUKINSA, a BTK inhibitor used to treat B-cell malignancies; TEVIMBRA, a PD-1 antibody for solid tumors; and medicines marketed under license in… From the company’s description.
In fiscal 2025, BeOne Medicines Ltd. reported revenue of $5.34B, up 40.2% from fiscal 2024, and net income of $286.93M. Its operating margin was 8.4%, and operations generated $1.13B in cash. Over the twelve months to Jun 30, 2026, revenue was $6.13B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BeOne Medicines Ltd. does
In the company’s own words
BeOne Medicines Ltd. (Nasdaq: ONC) is a global oncology company that discovers, develops and commercializes cancer medicines for patients worldwide. Its portfolio includes BRUKINSA, a BTK inhibitor used to treat B-cell malignancies; TEVIMBRA, a PD-1 antibody for solid tumors; and medicines marketed under license in China, including XGEVA, BLINCYTO and KYPROLIS. Sonrotoclax, a BCL2 inhibitor, received its first regulatory approval in China in 2025. The company’s pipeline spans hematologic and solid tumors and includes small molecules, protein degraders, bispecific antibodies and antibody-drug conjugates. BeOne sells its medicines in more than 60 markets and holds global commercial rights to several internally developed products, while also commercializing licensed products in defined territories. Its customers include healthcare providers and payors, with medicines reaching cancer patients through health systems, insurers and other channels. The company generated approximately $5.3 billion in total revenue in 2025 and had nearly 12,000 employees worldwide.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BASEL
- Fiscal year end
- December
- CIK
- 1651308
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BeOne Medicines Ltd. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BeOne Medicines Ltd.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
By share class
| Class | Held by funds | Funds | Shares out |
|---|---|---|---|
| BEIGF | — | 7 | — |
| ONC | — | 116 | — |
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BeOne Medicines Ltd. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BeOne Medicines Ltd.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BeOne Medicines Ltd.'s last four quarterly filings that the numbers alone won't show?”